Egcg    (DrugBank: EGCG)

9 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病1
8ハンチントン病1
13多発性硬化症/視神経脊髄炎6
17多系統萎縮症2
28全身性アミロイドーシス2
85特発性間質性肺炎1
113筋ジストロフィー2
206脆弱X症候群2
299嚢胞性線維症2

6. パーキンソン病 [臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,123 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00461942April 200617/4/2007Efficacy and Safety of Green Tea Polyphenol in De Novo Parkinson's Disease PatientsA Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Neuroprotection Effect of Green Tea Polyphenol in De Novo Parkinson's Disease PatientsParkinson's DiseaseDrug: Green Tea Polyphenols (EGCG/ECG)Xuanwu Hospital, BeijingMinistry of Health, China;Michael J. Fox Foundation for Parkinson's ResearchCompleted30 YearsN/ABoth480Phase 2China

8. ハンチントン病 [臨床試験数:197,薬物数:171(DrugBank:54),標的遺伝子数:82,標的パスウェイ数:144
Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 197 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01357681September 201119/5/2011Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease The ETON-Study - A Randomized, Double-blind, Stratified, Placebo-controlled Prospective Investigator Initiated Multicenter Trial -Huntington DiseaseDrug: (2)-epigallocatechin-3-gallate (EGCG);Drug: PlaceboCharite University, Berlin, GermanyNULLCompleted18 YearsN/ABoth54Phase 2Germany

13. 多発性硬化症/視神経脊髄炎 [臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228
Searched query = "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 3,050 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02011451December 201510/12/2013Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple SclerosisSafety and Neuroprotective Effects of Theaphenon 95% (95% Pure EGCG) in Multiple SclerosisMultiple SclerosisDrug: 95% Pure ECGC capsules 200mg;Drug: Placebo Comparator:Louisiana State University Health Sciences Center in New OrleansNational Multiple Sclerosis SocietyWithdrawn18 Years65 YearsBoth0Phase 2United States
2NCT01417312July 201115/8/2011Metabolic Effects of a Green Tea Extract in Multiple Sclerosis PatientsMultiple Sclerosis, Relapsing-RemittingDietary Supplement: Capsules with 160 mg Teavigo (at least 94% EGCG);Dietary Supplement: PlaceboCharite University, Berlin, GermanyNULLCompleted20 Years60 YearsAll20N/AGermany
3NCT00799890May 200928/11/2008Sunphenon in Progressive Forms of Multiple SclerosisMonocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple SclerosisMultiple SclerosisDrug: Sunphenon EGCG;Drug: PlaceboFriedemann PaulTAIYO EUROPECompleted18 Years65 YearsAll61Phase 2/Phase 3Germany
4NCT00525668September 20074/9/2007Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)Relapsing-remitting Multiple SclerosisDrug: epigallocatechin-gallate (Sunphenon);Drug: placeboCharite University, Berlin, GermanyNULLCompleted18 Years60 YearsAll120Phase 1/Phase 2Germany
5EUCTR2006-006323-39-DE19/06/200705/03/2007Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MSSunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS relapsing-remitting multiple sclerosisICD classification: G35.1Product Name: Sunphenon
Other descriptive name: Sunphenon EGCg TM
Charité-Universitätsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes
100Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2008-005213-22-DE22/08/2008SUPREMES - Sunphenon in progressive forms of multiple sclerosisSUPREMES - Sunphenon in progressive forms of multiple sclerosis - SUPREMES primary and secondary progressive forms of multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Sunphenon
Other descriptive name: Sunphenon EGCg
Charite Universitätsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes
60Phase 2;Phase 3Germany

17. 多系統萎縮症 [臨床試験数:107,薬物数:153(DrugBank:48),標的遺伝子数:59,標的パスウェイ数:104
Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 107 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02008721January 20148/12/2013Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-ApproachDouble-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA)Multiple System AtrophyDrug: EGCG as putative neuroprotective agent;Drug: PlaceboDr. Johannes LevinGerman Center for Neurodegenerative Diseases (DZNE);Deutsche Parkinson Vereinigung;Deutsche Stiftung Neurologie;ParkinsonFonds Deutschland gGmbHCompleted18 YearsN/ABoth92Phase 3Germany
2EUCTR2012-000928-18-DE21/11/201328/06/2013Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA)Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) - Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach Progression of patients with Multiple System Atrophy (MSA);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Sunphenon EGCg
INN or Proposed INN: EGCG
Other descriptive name: GREEN TEA LEAF
Hospital of the Ludwig-Maximilians-University of MunichNULLNot RecruitingFemale: yes
Male: yes
86Phase 3Germany

28. 全身性アミロイドーシス [臨床試験数:212,薬物数:234(DrugBank:72),標的遺伝子数:54,標的パスウェイ数:170
Searched query = "Systemic amyloidosis", "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 212 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02015312April 201318/11/2013A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)Light Chain (AL) Amyloidosis;Cardiac InvolvementDrug: Epigallocatechin-3-gallate (EGCG);Drug: PlaceboFlorian MichelGerman Federal Ministry of Education and ResearchCompleted18 YearsN/AAll38Phase 2Germany
2NCT01511263January 201210/1/2012Epigallocatechingallate (EGCG) in Cardiac AL AmyloidosisA Phase II Open-label Randomized Study of Dietary Supplement With Epigallocatechin Gallate (EGCG) to Improve Cardiac Dysfunction in Patients With AL Amyloidosis Who do Not Require Chemotherapy (EpiCardiAL)Primary Amyloidosis of Light Chain TypeDrug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias);Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCGIRCCS Policlinico S. MatteoNULLTerminated18 YearsN/AAll86Phase 2Italy

85. 特発性間質性肺炎 [臨床試験数:514,薬物数:377(DrugBank:108),標的遺伝子数:97,標的パスウェイ数:204
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 514 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03928847July 1, 201818/4/2019Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.Idiopathic Pulmonary FibrosisDrug: Epigallocatechin-3-gallate (EGCG)University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI)Recruiting40 Years70 YearsAll35Early Phase 1United States

113. 筋ジストロフィー [臨床試験数:567,薬物数:442(DrugBank:93),標的遺伝子数:55,標的パスウェイ数:151
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 567 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01183767December 30, 201017/8/2010Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular DystrophySunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: Epigallocatechin-Gallate;Drug: PlaceboCharite University, Berlin, GermanyNULLCompleted5 Years10 YearsAll33Phase 2/Phase 3Germany
2EUCTR2009-016482-28-DE25/06/201015/03/2010SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular DystrophySUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy - SUNIMUD Duchenne Muscular Dystrophy;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]Product Name: Sunphenon EGCG
INN or Proposed INN: Sunphenon
Charite Universitätsmedizin BerlinNULLNot RecruitingFemale: no
Male: yes
40Phase 2Germany

206. 脆弱X症候群 [臨床試験数:98,薬物数:73(DrugBank:27),標的遺伝子数:46,標的パスウェイ数:57
Searched query = "Fragile X syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 98 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03624556January 29, 20186/6/2018Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS)Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS)Down Syndrome;Fragile X SyndromeDietary Supplement: EGCG FontUp;Other: Placebo FontUpParc de Salut MarHospital Infantil Universitario Niño Jesús, Madrid, Spain;Instituto Hispalense de Pediatría, Sevilla, Spain;Hospital Universitario Marqués de Valdecilla;Institut Jerome LejeuneActive, not recruiting6 Years12 YearsAll70N/ASpain
2NCT01855971June 11, 20139/5/2013Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome (TESFX)Estrogen Receptors Beta (ER-B) as Therapeutic Targets for the Improvement of Cognitive Performance in Fragile-X (TESXF)Fragile X SyndromeDietary Supplement: EGCG;Dietary Supplement: Placebo;Other: Cognitive trainingParc de Salut MarNULLCompleted18 Years60 YearsAll44Phase 2Spain

299. 嚢胞性線維症 [臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 1,592 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-001259-29-GB12/03/201921/12/2018A study to establish the tolerabilty and adverse effects in people with a severe form of Cystic Fibrosi (delta F 508 homozygous) when using a combination of two products - cyteamine (a licensed medicine being used in a new disease) and EGCG (a food supplement).A PHASE 1B/2A STUDY TO ASSESS THE TOLERABILITY AND ADVERSE EFFECT PROFILE OF CYSTEAMINE (CYSTAGON) IN ADULTS AND CHILDREN WITH HOMOZYGOUS ?F508 CYSTIC FIBROSIS, IN PATIENTS TAKING EPIGALLOCATECHIN-3-GALLATE (EGCG, EPINERVE) FOOD SUPPLEMENTATION - Delta Dose Study DeltaF508 Homozygous Cystic Fibrosis
MedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Cystagon
Product Name: Cystagon
INN or Proposed INN: cysteamine bitartrate
Other descriptive name: 2-aminoethanethiol;2,3-dihydroxybutanedioic acid
University of LIverpoolNULLNot RecruitingFemale: yes
Male: yes
44Phase 1;Phase 2United Kingdom
2NCT00889434November 1, 201120/4/2009Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF)Single-site, Open-label, Dose-ranging, Efficacy, and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated CFCystic FibrosisDietary Supplement: ECGC;Dietary Supplement: Tocotrienol;Dietary Supplement: EGCG + TocotrienolHadassah Medical OrganizationNULLCompleted18 YearsN/AAll7N/AIsrael